Literature DB >> 27756973

The management of gout.

Andrew Finch Rheumatology1, Paul Kubler Rheumatologist1.   

Abstract

Gout is a common inflammatory arthritis that is increasing in prevalence. It is caused by the deposition of urate crystals. Non-steroidal anti-inflammatory drugs, colchicine and corticosteroids are options for the management of acute gout. They are equally efficacious and comorbidities guide the best choice. Allopurinol is an effective treatment for reducing concentrations of uric acid. Renal function guides the starting dose of allopurinol and the baseline serum uric acid concentration guides the maintenance dose. Febuxostat is another xanthine oxidase inhibitor. It is clinically equivalent to allopurinol. Uricosuric drugs, such as probenecid, increase uric acid excretion. New drugs in this class will soon become available and are likely to have a role in the treatment of patients who do not respond to other drugs.

Entities:  

Keywords:  allopurinol; febuxostat; gout; uric acid

Year:  2016        PMID: 27756973      PMCID: PMC4993710          DOI: 10.18773/austprescr.2016.047

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


  18 in total

Review 1.  Meat consumption and gout: Friend, foe or neither?

Authors:  Giuseppe Lippi; Camilla Mattiuzzi; Gianfranco Cervellin
Journal:  Rheumatol Int       Date:  2015-03-21       Impact factor: 2.631

2.  2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Authors:  Dinesh Khanna; John D Fitzgerald; Puja P Khanna; Sangmee Bae; Manjit K Singh; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

3.  Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.

Authors:  Garry G Graham; Diluk R W Kannangara; Sophie L Stocker; Ian Portek; Kevin D Pile; Praveen L Indraratna; Indira Datta; Kenneth M Williams; Richard O Day
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

Review 4.  Epidemiology of gout: an update.

Authors:  E U R Smith; C Díaz-Torné; F Perez-Ruiz; L M March
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-12       Impact factor: 4.098

5.  Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.

Authors:  Lisa K Stamp; William J Taylor; Peter B Jones; Jo L Dockerty; Jill Drake; Christopher Frampton; Nicola Dalbeth
Journal:  Arthritis Rheum       Date:  2012-08

Review 6.  Advances in pharmacotherapy for the treatment of gout.

Authors:  Philip C Robinson; Nicola Dalbeth
Journal:  Expert Opin Pharmacother       Date:  2014-12-30       Impact factor: 3.889

7.  Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial.

Authors:  Thomas H Taylor; John N Mecchella; Robin J Larson; Kevin D Kerin; Todd A Mackenzie
Journal:  Am J Med       Date:  2012-11       Impact factor: 4.965

8.  Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.

Authors:  K R Hande; R M Noone; W J Stone
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

Review 9.  A prescription for lifestyle change in patients with hyperuricemia and gout.

Authors:  Hyon K Choi
Journal:  Curr Opin Rheumatol       Date:  2010-03       Impact factor: 5.006

Review 10.  A review of uric acid, crystal deposition disease, and gout.

Authors:  Fernando Perez-Ruiz; Nicola Dalbeth; Tomas Bardin
Journal:  Adv Ther       Date:  2014-12-23       Impact factor: 3.845

View more
  1 in total

1.  Driveline Sepsis Presenting As Gout.

Authors:  Brittney Toms
Journal:  Cureus       Date:  2020-03-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.